Roche's Columvi Achieves Primary Endpoint of Prolonged Overall Survival in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Trial Roche reported that the Phase III STARGLO trial successfully achieved its main goal of improving overall survival. The research revealed that in...
Find MoreDate of Abstract presentation11th December 2023IndicationsAggressive B-cell lymphoma (a-BCL)Abstract Number4459Abstract typePoster Approximately 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) experience relapse following initial treatment with rituximab, cyclophosphamide, doxorubicin, vincr...
Find MoreDate of Abstract presentation9th December 2023IndicationsRelapsed/Refractory (r/r) Large B-Cell and Follicular LymphomasAbstract Number2095Abstract typePoster Despite the rising clinical fascination with autologous CAR T-cell therapies for hematologic malignancies and their noteworthy achievements, persistent ch...
Find MoreDate of Abstract presentation11th December 2023IndicationsDiffuse large B-cell lymphoma (DLBCL)Abstract Number4496Abstract typePoster Diffuse large B-cell lymphoma (DLBCL) stands as a swiftly progressing and aggressive ailment, representing the predominant type of non-Hodgkin lymphoma (NHL) and encompassing one-...
Find MoreDate of Abstract presentation10th December 2023IndicationsDiffuse Large B-cell lymphoma (DLBCL)Abstract Number436Abstract typeOral Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-c...
Find MoreDate of Abstract presentation9th December 2023IndicationsLarge B-cell lymphoma (LBCL)Abstract Number105Abstract typeOral For those patients with large B-cell lymphoma (LBCL) who remain uncured following initial treatment, the conventional approach for second-line therapy has been the utilization of high-dose che...
Find MoreDisc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera On Sept. 20, 2023, Disc Medicine, Inc. (NASDAQ: IRON) announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to MWTX-003 for the treatment of patients with Polycyt...
Find MoreSanofi to Acquire Provention Bio for USD 2.9 Billion Sanofi and Provention Bio, Inc., a publicly traded biopharmaceutical company based in the United States focused on intercepting and preventing immune-mediated diseases such as type 1 diabetes (T1D), have agreed to acquire Provention Bio, Inc. for $25.00 per sh...
Find MoreIn the year 2000, the first-ever Antibody-drug Conjugate (ADC) - Mylotarg, was launched by Pfizer and was considered a miracle in cancer treatment. And it appeared like there was no looking back for these antibody-drug conjugates. But it took almost another 11 years for the next ADC to launch in the market - Adectr...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.